Caring for ME Lunch & Learn Webinar Opioid Prescribing Regulations Updates on Chapter 488 and Related Rules

Size: px
Start display at page:

Download "Caring for ME Lunch & Learn Webinar Opioid Prescribing Regulations Updates on Chapter 488 and Related Rules"

Transcription

1 Caring for ME Lunch & Learn Webinar Opioid Prescribing Regulations Updates on Chapter 488 and Related Rules Gordon H. Smith, Esq. January 23, 2018, 12-1 pm Audio is available through your computer speakers For audio by phone, call (US Toll) and enter Webinar ID#

2 Thank You to Our Sponsor! Funding for this Caring for ME webinar series is provided by: The Maine Attorney General s Office

3 QC Staff is Working to Improve the Health of Everyone in Maine

4 QC Brings Together the People Who Give, Get and Pay for Health Care to Address Shared Priorities

5 Join Us! Become a Maine Quality Counts Member Learn About Becoming a Member: visit mainequalitycounts.org & click Membership Networking events Webinars with national experts

6 Caring for ME Be Part of the Solution! In April 2016, Maine Quality Counts (QC) and Maine Medical Association (MMA) launched Caring for ME, a collaborative effort that aims to bring together a wide set of partners to promote shared messages, educational resources, and practical tools for health care providers. Support prevention efforts Maintain a compassionate and trauma-informed approach to chronic pain management Improve the safety of opioid prescribing Appropriately diagnose addiction when it exists Improve access to effective treatments for patients with substance use disorder Join QC & MMA in Caring for Maine and be part of the solution!

7 Important Webinar Notes You are in view-only mode. Please use the Q&A function to ask questions & make comments Video screen size and location is adjustable. Tomorrow you will receive an with a link to the presentation recording and slides a link to the CME / CEU survey This webinar will be archived at

8 CME Available! CME will be available for participants who have signed into the live webinar. If you did not log into this webinar with your , submit your name and address using the Q&A feature on the tool bar at the bottom of your screen. We do not have separate CEUs for nursing staff or other healthcare professionals - but you may request a CME certificate as certificate of attendance. You must complete the survey in order to receive a certificate. Please complete the survey within 1 week. A CME certificate will be ed once the survey has closed.

9 CME Disclosure The speakers today do not have any relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this activity.

10 Today s Speaker: Gordon H. Smith, Esq. Gordon Smith is Executive Vice President of the Maine Medical Association. He graduated from the University of Maine with highest distinction and from the Boston College Law School, magna cum laude. He currently serves on the Executive Committee of the AMA Advocacy Resource Center, and is a member of the Board of Directors of the Daniel Hanley Center for Health Leadership. A frequent lecturer to medical groups on various medical legal subjects, Mr. Smith has served as EVP of the Maine Medical Association since September 1993.

11 Update on Chapter 488 and Associated Rules on Prescribing Opioid Medication Gordon H. Smith, Esq. Maine Medical Association Jan.23, 2018 Caring for ME Webinar

12 Disclosure There are no significant or relevant financial relationships to disclose.

13 This presentation is funded in part by a contract with:

14 Opioids: the difficult truth We know of no other medication routinely used for a nonfatal condition that kills patients so frequently. NEJM: 374; Dosage >200 MME: Number Needed to Kill = 32

15 More than One Death per Day Maine leads nation in rate of longacting opioid prescriptions Overdose death rate in Maine increased 40% from 2015 to Mainers lost to opioid/heroin deaths in overdose deaths in 2016 (313 involving opioids) 180 overdose deaths in first six months of 2017 Contrast: During the last decade, there were 258 homicides in Maine. There were 156 traffic fatalities in Maine in 2015.

16 1,024 Maine Babies Drug Affected in ,013 in 2015 but Fewer than 1000 in 2017 Maine s infant mortality rate (7.1/1000) exceeds the national average 1 out of every 11 babies in Maine was born drug-affected in 2016 Modest reduction in 2017 but still more than 3 drug affected babies born each day

17 Prescribing of Opioid Medication for Pain Continues to Decline Has declined since 2011 Number of high dose prescriptions (greater than 90 MME) fell 41.4% 2010 to 2015 Maine saw a 20% decline in the number of scripts from first half of 2016 to first half of 2017 Maine s prescribing declined 21.5% , the 4 th largest drop in the nation

18 Opioid Use Disorder It is estimated that 28,000 Mainers have Opioid Use Disorder with capacity to treat only 3500 to 7000

19

20 Maine Leads the Nation Maine leads the nation in prescribing long acting opioids at 21.8 Rx/100 people based on 2012 data published by CDC in to 65 pills prescribed for every man, woman and child in Maine annually.

21 Evidence of Over-Prescribing C-Section patients 1 53% report taking no or very few (<5) opioid pills prescribed postoperatively 83% report taking half or fewer Thoracic surgery patients 1 45% report taking no or very few (<5) opioid pills prescribed postoperatively 71% report taking half or fewer 1: PLoS One ;11(1); e Epub 2016 Jan

22 Growing Evidence of Over-Prescribing General surgery patients 2 75% partial mastectomy pts did not take any of their prescribed opioids 34% lap choly pts took no prescribed opioids 45% lap inguinal hernia pts took no prescribed opioids Pts reported having 67% to 85% opioid pills remaining Wisdom tooth extraction patients 3 On average, received 28 pills but used <50% of amount prescribed Extrapolates to >100 million opioid pills unused nationally! 2: Ann Surg, Hill et al, Sept 14, : Drug Alcohol Depend Nov 1; Epub 2016 Sep 20.

23 Maine Opiate Collaborative

24 Civics 101: A Refresher Levels of authority: 1. Statutes: Passed by Legislature, signed by Governor Identified as P.L. 2015, c. 508 or 22 MRSA 2353 (2015) Major policy directives 2. Rules/Regulations Drafted by Departments (DHHS) or Boards (BOLIM) Adopted after public comment More detailed than statutes, explanatory Identified as C.M.R. ch.11, 4 (2017) Rules are subordinate to statutes

25 Overview of P.L. 2015, Chapter 488 Effective 90 days after adjournment of the Second Regular Session of the 127 th Maine Legislature, though some provisions have other timeframes specified (July 29, 2016) As Amended by P.L. 2017, Chapter 213 As further described by OSAMHS Rule Chapter 11, Rules Governing the Controlled Substances Prescription Monitoring Program and Prescription Opioid Medications Components include: Required PMP check for prescribers and dispensers (1/1/2017) Prescribing limits on MMEs per day (7/29/2016) Prescribing limits on length of scripts (1/1/2017) Exception for emergency rooms, inpatient hospitals, long-term care facilities, or residential care facilities or in connection with a surgical procedure. Exception for medication-assisted treatment for substance use disorder Exceptions for active and aftercare cancer treatment, palliative care, and end-of-life and hospice care Other exceptions may be determined by rule Mandatory CME (12/31/2017) Mandatory electronic prescribing (7/01/2017) Partial filling of prescriptions at patient request (7/29/2016)

26 Key Definitions Acute pain Normal, predicted physiological response to a noxious chemical or thermal or mechanical stimulus Typically associated with invasive procedures, trauma or disease and is usually time-limited Chronic pain Persists beyond the usual course of an acute disease or healing of an injury May or may not be associated with an acute or chronic pathologic process that causes continuous or intermittent pain over months or years

27 Opioid medication Key Definitions A controlled substance containing an opioid; includes tramadol, does not include loperamide Prescriber Licensed health care professional with authority to prescribe controlled substances Includes MDs, DOs, PAs, NPs, podiatrists, dentists, and veterinarians Administer Action to apply prescription drug directly to a person by any route by a licensed or certified health care professional (the statute and rule do not define order, as in ordering a medication to be administered by an RN) Does not include delivery, dispensing, or distribution of a prescription drug for later use

28 Key Definitions Palliative care Patient-centered, family-focused medical care that optimizes quality of life by anticipating, preventing, and treating suffering caused by serious medical illness or physical injury or condition that substantially affects quality of life Addresses physical, emotional, social, and spiritual needs Facilitates patient autonomy and choice of care Provides access to information Discusses patient s goals for treatment and treatment options, including hospice care, when appropriate Manages pain and symptoms comprehensively Palliative care does not always include a requirement for hospice care or attention to spiritual needs. (new) Note: Does not require a terminal condition

29 Key Definitions Serious illness Medical illness or physical injury or condition that substantially affects quality of life for more than a short period of time Includes, but is not limited to, Alzheimer s disease and related dementias, lung disease, cancer and heart, renal or liver failure and chronic, unremitting or intractable pain such as neuropathic pain. (new)

30 Prescriber Responsibilities Required PMP check Upon initial prescription of benzodiazepine or opioid medication Every 90 days following Delegation of PMP check Prescribers may delegate PMP check to any staff member duly authorized by prescriber/practice and PMP Office Despite delegation, prescriber must review patient s aggregate MME (including new prescription); number of prescribers currently prescribing controlled substances to patient; and number of pharmacies currently dispensing

31 Exception to PMP Check No PMP check is required for benzodiazepine or opioid medication directly administered in an emergency room setting, an inpatient hospital setting, a long-term care facility (assisted living or nursing home), or a residential care facility, or in connection with a surgical procedure. No PMP check is required for hospice or end-oflife patients.

32 Prescriber Responsibilities Required notations on opioid prescriptions DEA number Acute or Chronic for all prescriptions (including suboxone) under 100 MME and Exemptions F and H For acute on chronic pain (Exemption Code F), use Acute For palliative care (Exemption Code B), note the diagnosis (ICD-10) code Where an exemption is claimed, the exemption code (A through H) must be noted New: Pharmacists may contact prescribers by telephone to verify and document missing information on the script.

33 Exceptions to limits on opioid medication prescribing By Statute 1. Pain associated with active and aftercare cancer treatment. Providers must document in the medical record that the pain experienced by the individual is directly related to the individual s cancer or cancer treatment. Exemption Code A 2. Palliative care in conjunction with a serious illness (includes injury). Code B, (ICD 10 Code must be included on script as well as Code B ) 3. End-of-life and hospice care. Code C 4. Medication-Assisted Treatment for substance use disorder. Code D

34 Exceptions to limits on opioid medication prescribing By Rule 5. A pregnant individual with a pre-existing prescription for opioids in excess of the 100 Morphine Milligram Equivalent aggregate daily limit. Exemption applies only during the duration of the pregnancy. Code E 6. Acute pain over an existing opioid prescription for chronic pain. The acute pain must be postoperative or new onset. Seven day prescription limit applies. Code F 7. Active taper of opioid medications, maximum taper period of six months, after which time the opioid limitations will apply, unless one of the additional exceptions in this subsection apply. Code G 8. Prescription of a second opioid after proving intolerant to a first opioid, thereby exceeding the 100 MME limit. Neither prescription may exceed 100 MME. Code H

35 Prescriber Responsibilities Continuing Education Every prescriber must complete 3 hours of CME on the prescription of opioid medication every 2 years as a condition of prescribing opioid medication First 3 hours must be completed by 12/31/2017. Electronic Prescribing Prescribers with the capability to electronically prescribe must prescribe all opioid medication electronically A waiver may be available in some circumstances: Written waiver application required Penalties for failure to comply

36 E-prescribing Mandate MMA relationship with Dr. First. Contact is Eric Landry at or No exceptions for any specialties, locations Long term care facilities may use fax per DEA rules For homeless patients, use address of shelter, street name, if possible; if no address, may prescribe on paper Exemption from limits/pmp checks is NOT exemption from E-prescribing requirement

37 E-prescribing Mandate - Exceptions Exceptional circumstances allowing written prescriptions: Temporary technological or electrical failure To be dispensed by VA or Indian Health Service pharmacy, or outside Maine Prescriber reasonably determines that it would be impractical, patient could not obtain medication timely, and delay would adversely impact patient s medical condition

38 Partial fill Upon patient request, pharmacist may dispense lesser quantity of medication than is prescribed Remainder of prescription is void Pharmacist must, within 7 days, notify prescriber of quantity actually dispensed Notification may be by notation in patient s EHR, by electronic transmission or fax or telephone In cases of pharmacist shortage, lesser quantity may be dispensed. Remainder may be dispensed only if within 72 hours.

39 Penalties Civil violation Subject to fine of $250 per incident up to a maximum of $5000 per calendar year More serious concern is Licensing Board action PMP will report violations to Board, prescriber will receive 2 weeks advance notice and opportunity to comment

40 What will the Maine CDC Be Looking For? High number of prescribers in a short time High number of doses in a short time Days supply of prescriptions for the same drug overlapping by more than a few days Inappropriate combinations of controlled substances More than one method of payment within a short time More than one out-of-state prescriber for the same patient, within a short time More than one pharmacy on the same day More than one pharmacy in different public health districts within one month Dangerous levels of specific drugs

41 COMING VERY SOON Licensing Boards: Revised version of Joint Rule, Chapter 21 Universal opioid precautions (exception for medical emergency) Risk assessment tool encouraged, assessment must be documented Use measuring tools to assess level of pain, function, quality of life Random toxicological drug screens required at least annually Frequency based on patient s level of risk Random pill counts an additional tool, probably not mandatory Treatment agreement, informed consent rules detailed & mandatory These requirements mostly for chronic pain prescriptions

42 More Regulatory and Legislative Activity Licensing Boards: CME (Chapter 1) MDs: All must have 3 hours of opioid CME every 2 years, regardless of opioid prescribing, starting in 2018 Other Boards: Only as condition of prescribing opioids MaineCare rules Limit of 4 acute pain prescriptions (28 days) Legislative Task Force on the Opioid Crisis Recommendations Currently Under Discussion

43 Resources MMA s Opioid Crisis page: Opioid laws & rules, Maine Opiate Collaborative task force Reports, CDC guidelines, naloxone, Q and A, DHHS clarifications. Caring for ME page: Webinars, opioid laws & rules, information on pain management and tapering, etc.

44 Questions? Maine Medical Association 30 Association Drive, P.O. Box 190 Manchester, Maine Fax Gordon Smith, Esq. Andrew MacLean, Esq. Peter Michaud, Esq.

45 Upcoming Caring for ME Webinars Tues, February 6, 2018, 12-1 pm, Caring for ME Webinar: Alternative Treatments for Pain, Elisabeth Fowlie Mock, MD, MICIS, Register via zoom Tues, March 13, 2018, 12-1 pm, Caring for ME Webinar: Snuggle ME Guidelines: What s New?, Kelley Bowden, Zoom Registration Tues, May 15, 2018, 12-1 pm: Caring for ME Webinar: Setting up MAT Programs in the Emergency Department: Ranjiv Advani MD & Leah Bauer MD, Midcoast Hospital, Register via zoom Tues, June 12, 2018, 12-1 pm, Caring for ME Webinar: Integrated Care for Pregnant and Parenting Women with Opioid Use Disorders: Best Practice with Limited Resources, Daisy Goodman, DNP, Zoom Registration

46 QC launched 6 Online CME Modules with the Support of the Board of Licensure in Medicine (BOLIM) and the MMA in August of Compliance with Maine Prescribing Laws Safe Opioid Prescribing & Prescribing Limits Chronic Pain Management Appropriate Diagnosis and Treatment of Opioid Addiction Safe & Compassionate Opioid Tapering Maternity Care and the Snuggle ME Guidelines

The Opioid Crisis: Effectiveness of State Responses

The Opioid Crisis: Effectiveness of State Responses The Opioid Crisis: Effectiveness of State Responses Gordon H. Smith, Esq. Maine Medical Association American Society of Medical Association Counsel Mauna Lani Bay, November 2017 Opioids: the difficult

More information

Update on Maine Laws and Associated Rules on Prescribing Opioid Medication

Update on Maine Laws and Associated Rules on Prescribing Opioid Medication Update on Maine Laws and Associated Rules on Prescribing Opioid Medication Gordon H. Smith, Esq. Executive Vice President Maine Medical Association 2018 Disclosure There are no significant or relevant

More information

Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers

Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers Gordon H. Smith, Esq., Executive Vice President Maine Medical Association May 3, 2016 Facing the Opioid Crisis Today Opioid

More information

Update on Maine Laws and Associated Rules on Prescribing Opioid Medication

Update on Maine Laws and Associated Rules on Prescribing Opioid Medication Update on Maine Laws and Associated Rules on Prescribing Opioid Medication Gordon H. Smith, Esq. Executive Vice President Maine Medical Association 2018 Disclosure There are no significant or relevant

More information

Prescription Monitoring Program (PMP)

Prescription Monitoring Program (PMP) 06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid

More information

Caring for ME Pharmacy Lunch & Learn Webinars

Caring for ME Pharmacy Lunch & Learn Webinars Caring for ME Pharmacy Lunch & Learn Webinars Opioid Prescribing Regulations : Updates on Chapter 488 and Related Rules Audio is available through your computer speakers For audio by phone, call 1-646-558-8656

More information

MICIS 2017 REPORT January 1 - December 31, 2017

MICIS 2017 REPORT January 1 - December 31, 2017 MICIS 2017 REPORT January 1 - December 31, 2017 MICIS, the Maine Independent Clinical Information Service, has been providing evidence-based prescribing education in Maine since 2008. 2017 Program The

More information

2016 Dr. Douglas H. Kay CPE Symposium

2016 Dr. Douglas H. Kay CPE Symposium GREGORY CAMERON, R.Ph ASSISTANT PROFESSOR OF PHARMACY PRACTICE FIELD COORDINATOR COMMUNITY SITES HUSSON UNIVERSITY SCHOOL OF PHARMACY November 5, 2016 Please Silence All Electronic Equipment OBJECTIVES

More information

Caring for ME Lunch & Learn Webinar

Caring for ME Lunch & Learn Webinar Caring for ME Lunch & Learn Webinar Hub and Spoke Model: Creating a Substance Use Disorder Services System of Care in Vermont Successes, Challenges and Future Opportunities Beth Tanzman, Director Blueprint

More information

MeHAF Addiction Care Grantee Meeting #3 Building Capacity. May 23, :30 AM 3:30 PM Maple Hill Farms

MeHAF Addiction Care Grantee Meeting #3 Building Capacity. May 23, :30 AM 3:30 PM Maple Hill Farms MeHAF Addiction Care Grantee Meeting #3 Building Capacity May 23, 2018 9:30 AM 3:30 PM Maple Hill Farms Welcome to All Grantees and Project Partners! Welcome to our Guests! Community Members with Lived

More information

OPIOID. Opioid Legislation FAQs NEED TO KNOW

OPIOID. Opioid Legislation FAQs NEED TO KNOW OPIOID MICHIGAN OSTEOPATHIC ASSOCIATION APRIL 5, 2018 NEED TO KNOW Opioid Legislation FAQs These FAQs represent a compilation of questions received from MSMS and MAFP members. Please note that this is

More information

MeHAF Addiction Care Learning Session #2. September 13, :30 AM 3:30 PM Augusta Civic Center

MeHAF Addiction Care Learning Session #2. September 13, :30 AM 3:30 PM Augusta Civic Center MeHAF Addiction Care Learning Session #2 September 13, 2017 9:30 AM 3:30 PM Augusta Civic Center Welcome to All Grantees and Project Partners! The Importance of Collective Impact Tackling the Tough Topics

More information

Understanding Maine s Medical Marijuana Law

Understanding Maine s Medical Marijuana Law Understanding Maine s Medical Marijuana Law Maine Pharmacy Association May 20, 2011 Background 1999: Maine Medical Marijuana Act passes as initiated bill (I.B.) Authorizes medical use of marijuana for

More information

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

On December 27, 2017, the Lieutenant Governor signed into law several new requirements OPIOID Alert MICHIGAN OSTEOPATHIC ASSOCIATION JANUARY 2018 On December 27, 2017, the Lieutenant Governor signed into law several new requirements aimed at combating the opioid epidemic. On the following

More information

Maine s Response to the Opiate Crisis. Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016

Maine s Response to the Opiate Crisis. Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016 Maine s Response to the Opiate Crisis Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016 Required Disclosure Text Font typically Times New Roman at least 20 point Try

More information

California. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

MeHAF Addiction Care Grantee Meeting #3 Building Capacity. October 3, :30 AM 3:30 PM Maple Hill Farms

MeHAF Addiction Care Grantee Meeting #3 Building Capacity. October 3, :30 AM 3:30 PM Maple Hill Farms MeHAF Addiction Care Grantee Meeting #3 Building Capacity October 3, 2018 9:30 AM 3:30 PM Maple Hill Farms Welcome to All Grantees and Project Partners! CME Disclosure The speakers today do not have any

More information

WHAT YOU NEED TO KNOW TO ABOUT AB 474

WHAT YOU NEED TO KNOW TO ABOUT AB 474 WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov

More information

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update Bureau of Professional Licensing MAPS Updates & Opportunities April 28, 2018 Presented by Andrew Hudson, Manager Haley Winans, Analyst Drug Monitoring Section Bureau of Professional Licensing BPL-MAPS@Michigan.gov

More information

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Public Health Impacts of 2016 West Virginia Legislation

Public Health Impacts of 2016 West Virginia Legislation Public Health Impacts of 2016 West Virginia Legislation Sherri A. Young, DO, FAAFP WVSOM Summer Seminar North Myrtle Beach, South Carolina June 15, 2016 1 Objectives Passage and implementation of Expedited

More information

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin. The Wisconsin Prescription Drug Monitoring Program Wisconsin Nurses Association Jail Health Care Conference May 21, 2018 WI PDMP Timeline PDMP Overview January 2013 WI PDMP operational April 2017 WI epdmp

More information

Objectives 1/25/18. An Update on Controlled Substance Prescribing Laws & Rules for CNMs. Exclusionary Formulary Effective: May 17, 2017

Objectives 1/25/18. An Update on Controlled Substance Prescribing Laws & Rules for CNMs. Exclusionary Formulary Effective: May 17, 2017 1/25/18 An Update on Controlled Substance Prescribing Laws & Rules for CNMs Keeley Harding, DNP, APRN, CPNP-AC/PC February 4, 2018 2018 Ohio ACNM Forward Kalahari Resorts and Conference Center, Sandusky,

More information

The Wisconsin Prescription Drug Monitoring Program

The Wisconsin Prescription Drug Monitoring Program The Wisconsin Prescription Drug Monitoring Program DHS 2018 WI Opioid Forum April 12, 2018 Learning Objectives 1. How the WI epdmp supports healthcare professionals in making informed prescribing, dispensing

More information

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Scott M. Gagnon, MPP, PS-C Director, AdCare Educational Institute of Maine, Inc. Co-Chair, Prevention & Harm

More information

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26)

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26) H GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH0-MGfa-H* (01/) H.B. Mar, HOUSE PRINCIPAL CLERK D Short Title: Strengthen Opioid Misuse Prevention (STOP)Act. (Public) Sponsors: Referred to:

More information

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New

More information

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

D. Todd Bess, PharmD 1

D. Todd Bess, PharmD 1 s Program as a Tool to Improve Patient Care and Fight the Drug Epidemic D. Todd Bess, Pharm.D. Director April 12, 2018 Disclosure Information I have no financial relationships to disclose. I will not discuss

More information

Maine s Medical Marijuana Law. 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014

Maine s Medical Marijuana Law. 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014 Maine s Medical Marijuana Law 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014 Medical Marijuana Laws Alaska (1998) Arizona (1996, 2010) California (1996) Colorado (2000) Delaware

More information

Opioid Abuse and Prescribing. Dr. Mitchell Mutter Director of Special Projects

Opioid Abuse and Prescribing. Dr. Mitchell Mutter Director of Special Projects Opioid Abuse and Prescribing Dr. Mitchell Mutter Director of Special Projects Auburn University February 22, 2019 Disclosure Statement of Financial Interest I, Mitchell Mutter, DO NOT have a financial

More information

PRESCRIBING GUIDELINES

PRESCRIBING GUIDELINES Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy

More information

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable Alaska Requires adoption of regulations that provide that a practitioner query the PDMP prior to dispensing, prescribing, or administering a Sch. II or III controlled substance; query is not required for

More information

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Illinois Prescription Monitoring Program Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Agenda Provide an overview of the Illinois Prescription Monitoring Program

More information

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

btute PUBLIC CHAPTER NO. 1039

btute PUBLIC CHAPTER NO. 1039 btute of @ennennee PUBLIC CHAPTER NO. 1039 HOUSE BILL NO. 1831 By Representatives Hawk, Gasada, Kumar, Johnson, Gameron Sexton, Terry, Powers, Coley, Daniel, Eldridge, Holsclaw, Favors, Hardaway Substituted

More information

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW HOUSE BILL 243

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW HOUSE BILL 243 GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW 2017-74 HOUSE BILL 243 AN ACT STRENGTHENING OPIOID MISUSE PREVENTION BY EXTENDING STANDING ORDERS FOR OPIOID ANTAGONIST TO COMMUNITY HEALTH GROUPS;

More information

Rule Governing the Prescribing of Opioids for Pain

Rule Governing the Prescribing of Opioids for Pain Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This

More information

North Dakota Board of Pharmacy

North Dakota Board of Pharmacy North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives

More information

MQAC Rules for the Management of Chronic Non-Cancer Pain For Allopathic Physicians Effective January 2, 2012

MQAC Rules for the Management of Chronic Non-Cancer Pain For Allopathic Physicians Effective January 2, 2012 MQAC Rules for the Management of Chronic Non-Cancer Pain For Allopathic Physicians Effective January 2, 2012 WAC 246-919-850 Pain management Intent. These rules govern the use of opioids in the treatment

More information

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

NOTICE OF INTENT. Department of Health and Hospitals Board of Dentistry

NOTICE OF INTENT. Department of Health and Hospitals Board of Dentistry NOTICE OF INTENT Department of Health and Hospitals Board of Dentistry Fees and Costs; Anesthesia/Analgesia Administration; Continuing Education Requirements (LAC 46:XXXIII.134,.306,.706,.1505,.1607,.1611,.1613,.1709,

More information

Readopt with amendment Med 502, effective (Document #11090), to read as follows:

Readopt with amendment Med 502, effective (Document #11090), to read as follows: Adopted Rules 11-2-16 1 Readopt with amendment Med 502, effective 5-3-16 (Document #11090), to read as follows: PART Med 502 OPIOID PRESCRIBING Med 502.01 Applicability. This part shall apply to the prescribing

More information

Proposed Revision to Med (i)

Proposed Revision to Med (i) Proposed Revision to Med 501.02 (i) I. Purpose This rule has been adopted to enable the Board to best protect public health and safety while providing a framework for licensees to effectively treat and

More information

Report to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program

Report to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp Minnesota Board of

More information

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

SUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy

SUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy SUBHEAD GOES HERE Addressing Tennessee s Opioid Crisis Natalie A. Tate, PharmD Vice President, Pharmacy Our opioids story Our approach Our response to neonatal abstinence syndrome Facts and faces of opioid

More information

2. Is this request for a preferred medication? Y N

2. Is this request for a preferred medication? Y N Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile New Mexico Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)? Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

E-Prescribing, EPCS & PDMP: An Update

E-Prescribing, EPCS & PDMP: An Update E-Prescribing, EPCS & PDMP: An Update Melissa A. Kotrys, MPH Chief Executive Officer July 27, 2018 Arizona Health-e Connection is now Health Current Arizona s primary resource for health information technology

More information

New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers

New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers CENTERS FOR MEDICARE & MEDICAID SERVICES New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers Background CMS understands the magnitude of the nation s opioid epidemic and

More information

Sub. S.B. 119 As Passed by the Senate

Sub. S.B. 119 As Passed by the Senate AM3404 Sub. S.B. 119 As Passed by the Senate Topic: Opioid Data and Communication Expansion Act moved to amend as follows: In line 1 of the title, after "4723.52," insert "4729.01, 4729.44, 4729.75, 4729.79,

More information

Vermont. Prescribing and Dispensing Profile. Research current through November 2015.

Vermont. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of

More information

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Virginia. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. Arizona Corporate Counsel Presentation May 8, 2018 Agenda 1. Overview of the Opioid

More information

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable Alabama Requirements for use of the PMP, including the following: 1) when prescribing a patient a controlled substance of more than 30 MME per day, physicians shall query the PMP for that patient at least

More information

Maine Child Health Improvement Partnership (ME CHIP) Advisory Group Friday, February 9, 1-2 pm

Maine Child Health Improvement Partnership (ME CHIP) Advisory Group Friday, February 9, 1-2 pm Maine Child Health Improvement Partnership (ME CHIP) Advisory Group Friday, February 9, 1-2 pm Webinar/Phone https://zoom.us/j/5211733487 or phone 14086380968,,,5211733487# Maine Child Health Improvement

More information

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6

More information

Our Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System

Our Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System Our Journey to Addressing the PA PDMP Program Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System 1 Geisinger Health System Geisinger Health System is an integrated

More information

MOA: Practice Managers Program. Presented by: Kimber Debelak, CMC, CMOM, CMIS. May 17, zpain Management. & New Opioid Laws

MOA: Practice Managers Program. Presented by: Kimber Debelak, CMC, CMOM, CMIS. May 17, zpain Management. & New Opioid Laws MOA: Practice Managers Program Presented by: Kimber Debelak, CMC, CMOM, CMIS May 17, 2018 Pain Management & New Opioid Laws Objectives and Educational Statement Objectives To understand the need for new

More information

TN Opioid Program. Erica Schlesinger, Pharm.D

TN Opioid Program. Erica Schlesinger, Pharm.D TN Opioid Program Erica Schlesinger, Pharm.D Nothing to disclose Disclosures TN Together Governor Haslam s Plan Prevention Establishes limits, decreases supply and dosage of prescription opioids Limits

More information

MORPHINE MILLIGRAM EQUIVALENTS (MMEs) Elisabeth Fowlie Mock, MD, MPH, FAAFP Maine Quality Counts Caring For ME Webinar 11/8/2016

MORPHINE MILLIGRAM EQUIVALENTS (MMEs) Elisabeth Fowlie Mock, MD, MPH, FAAFP Maine Quality Counts Caring For ME Webinar 11/8/2016 MORPHINE MILLIGRAM EQUIVALENTS (MMEs) Elisabeth Fowlie Mock, MD, MPH, FAAFP Maine Quality Counts Caring For ME Webinar 11/8/2016 Objectives By the conclusion of this webinar, the learner will have: Identified

More information

Prepublication Requirements

Prepublication Requirements Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals

More information

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists Background Opioid medications are effective at treating certain types of pain,

More information

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid

More information

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able

More information

Ontario s Narcotics Strategy

Ontario s Narcotics Strategy Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action

More information

Addressing the Opioid Epidemic in Tennessee

Addressing the Opioid Epidemic in Tennessee Addressing the Opioid Epidemic in Tennessee A Multidisciplinary Approach Melissa McPheeters, PhD, MPH Director, Informatics and Public Health Analytics 26 108 733 *Source: CDC References Centers for

More information

Request for Proposal. PA ACT 139 Naloxone Purchase

Request for Proposal. PA ACT 139 Naloxone Purchase Request for Proposal PA ACT 139 Naloxone Purchase Proposals due by February 6, 2014, 4:00PM 3905 N. Front Street Harrisburg, PA 17110-1536 Phone (717) 236-1059 Table of Contents PA ACT 139... I NALOXONE

More information

Opioid Prescribing Improvement Program

Opioid Prescribing Improvement Program Opioid Prescribing Improvement Program Jeff Schiff, MD, MBA, Medical Director of Minnesota Health Care Programs Sarah Rinn, MPH, Opioid Prescribing Improvement Program Coordinator Agenda Opioid Prescribing

More information

Opioid Review and MAT Clinic CDC Guidelines

Opioid Review and MAT Clinic CDC Guidelines 1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are

More information

CODE OF RHODE ISLAND RULES

CODE OF RHODE ISLAND RULES CODE OF RHODE ISLAND RULES AGENCY 14. DEPARTMENT OF HEALTH SUB-AGENCY 060. FOOD AND DRUG CONTROL CHAPTER 009. PAIN MANAGEMENT, OPIOID USE AND THE REGISTRATION OF DISTRIBUTORS OF CONTROLLED SUBSTANCES CRIR

More information

Section I. Short-acting opioid Prior Authorization Criteria

Section I. Short-acting opioid Prior Authorization Criteria Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization

More information

HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder

HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder Brett Giroir, U.S. Department of Health and Human Services Join the conversation at #OUDTreatment #EndTheStigma Expanding

More information

Protecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers

Protecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers Protecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers Audio is streaming through your computer speakers. If you

More information

Medicaid and the Opioid Crisis

Medicaid and the Opioid Crisis Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers

More information

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION AN ACT relating to public health and safety; creating the advisory council on palliative care; providing definitions; providing for council membership; providing duties for the council; providing duties

More information

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended

More information

Arizona State Office of Rural Health Webinar Series

Arizona State Office of Rural Health Webinar Series Arizona State Office of Rural Health Webinar Series Mute your phone &/or computer microphone Time is reserved at the end for Q&A Please fill out the post-webinar survey Webinar is being recorded Recording

More information

BOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director

BOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director BOARD OF PHARMACY- REGULATORY UPDATE Kimberly Grinston, J.D., Executive Director Disclosure and Conflict of Interest I declare no conflicts of interest, real or apparent, and no financial interest in any

More information

OPIOID PRESCRIBING RULES. May 17, 2017 Webinar

OPIOID PRESCRIBING RULES. May 17, 2017 Webinar OPIOID PRESCRIBING RULES May 17, 2017 Webinar Outline Introduction and Universal Precautions Dr. Levine, Commissioner, Health Department 15 Minutes Acute Pain Dr. Patti Fisher, UVMMC 20 Minutes Chronic

More information

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION AN ACT relating to public health and safety; creating the Emergency Administration of Opiate Antagonist Act; providing for prescription and administration of an opiate antagonist drug as specified; granting

More information

Impact of Opioid Prescribing Rules in Post Acute and Long Term Care

Impact of Opioid Prescribing Rules in Post Acute and Long Term Care Impact of Opioid Prescribing Rules in Post Acute and Long Term Care Jessica Van Fleet-Green, MD, FAAFP, CMD Chief Medical Officer, Physicians of Southwest Washington Medical Director, ManorCare Lacey History

More information

Preparing for Electronic Prescribing of Controlled Substances (EPCS) in New York

Preparing for Electronic Prescribing of Controlled Substances (EPCS) in New York Preparing for Electronic Prescribing of Controlled Substances (EPCS) in New York Ken Whittemore, Jr. R.Ph., MBA Senior VP, Professional & Regulatory Affairs Copyright Copyright 2015 by 2015 Surescripts,

More information

Report to the Legislature: Impact of the Minnesota Prescription Monitoring Program on Doctor Shopping

Report to the Legislature: Impact of the Minnesota Prescription Monitoring Program on Doctor Shopping Minnesota Board of Pharmacy Report to the Legislature: Impact of the Minnesota Prescription Monitoring Program on Doctor Shopping Prepared By: Dr. Katrina Howard, PMP Pharmacist Consultant October 31,

More information

Opioid Use Disorder and Medication Assisted Recovery: Caring For Our Communities

Opioid Use Disorder and Medication Assisted Recovery: Caring For Our Communities Opioid Use Disorder and Medication Assisted Recovery: Caring For Our Communities Speaker: Elisabeth Fowlie Mock, MD Tuesday, November 27, 2018 12 1 PM Audio is available through your computer speakers.

More information

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

Utah. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Utah Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view

More information

State, District, or Territory Criteria for Mandatory Query of PDMP

State, District, or Territory Criteria for Mandatory Query of PDMP State, District, or Territory Alabama Alaska Arizona Criteria for Mandatory Query of PDMP Requirements for use of the PMP, including the following: 1) when prescribing a patient a controlled substance

More information

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid

More information

2016 Jurisprudence Update. (Phone) (Fax)

2016 Jurisprudence Update. (Phone) (Fax) 2016 Jurisprudence Update (Phone) 614-466-4143 (Fax) 614-752-4836 www.pharmacy.ohio.gov Goals and Objectives To explain recent law/rule changes which may apply to the pharmacy practice setting. To describe

More information

Opioid Analgesic Treatment Worksheet

Opioid Analgesic Treatment Worksheet Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797

More information

SCRIPTS. South Carolina Reporting & Identification Prescription Tracking System

SCRIPTS. South Carolina Reporting & Identification Prescription Tracking System SCRIPTS South Carolina Reporting & Identification Prescription Tracking System Accidental Deaths 3 Due to Drug Overdose SC Occurrence Data Accidental Drug Overdose Year # of Deaths All deaths Drug not

More information

Progress Report and 2018 Legislative Opportunities. Maine Opiate Collaborative Recommendations

Progress Report and 2018 Legislative Opportunities. Maine Opiate Collaborative Recommendations Progress Report and 2018 Legislative Opportunities related to the Maine Opiate Collaborative Recommendations April 2018 A. Destigmatize substance use disorders within the law enforcement profession 1.

More information

ISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners.

ISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners. Code of New Mexico Rules Title 16. Occupational and Professional Licensing Chapter 17. Osteopathic Medicine and Surgery Practitioners Part 5. Prescribing and Distribution of Controlled Substances 16.17.5.

More information

RULE-MAKING ORDER PERMANENT RULE ONLY. CR-103P (December 2017) (Implements RCW )

RULE-MAKING ORDER PERMANENT RULE ONLY. CR-103P (December 2017) (Implements RCW ) CODE REVISER USE ONLY RULE-MAKING ORDER PERMANENT RULE ONLY CR-103P (December 2017) (Implements RCW 34.05.360) Agency: Department of Health- Dental Quality Assurance Commission Effective date of rule:

More information